Histone modifications underlie monocyte dysregulation in patients with systemic sclerosis, underlining the treatment potential of epigenetic targeting.

Maarten van der KroefMonica CastellucciMichal MokryMarta CossuMarianna GaronziLara M Bossini-CastilloEleni ChouriCatharina G K WichersLorenzo BerettaElena TrombettaSandra Silva-CardosoNadia VazirpanahTiago CarvalheiroChiara AngiolilliCornelis P J BekkerAlsya J AffandiKris A ReedquistFemke Bonte-MineurEls J M ZirkzeeFlavia BazzoniTimothy R D J RadstakeMarzia Rossato

Published in: Annals of the rheumatic diseases (2019)

SSc monocytes have altered chromatin marks correlating with their IFN signature. Enzymes modulating these reversible marks may provide interesting therapeutic targets to restore monocyte homeostasis to treat or even prevent SSc.

Keyphrases

systemic sclerosis
dendritic cells
interstitial lung disease
dna methylation
peripheral blood
gene expression
endothelial cells
immune response
genome wide
dna damage
signaling pathway
transcription factor
oxidative stress
replacement therapy
idiopathic pulmonary fibrosis